Monday, 18 October 2021


Korea's Genematrix receives CE-IVD mark for HPV detection kit

12 October 2021 | News

A real-time PCR-based human papillomavirus (HPV) detection product

image credit- prnewswire

image credit- prnewswire

South Korean biotech firm Genematrix has announced that 'NeoPlex™ HPV29 Detection', which can collectively diagnose 29 genotypes of human papillomavirus (HPV; the causative agent of cervical cancer) and simultaneously identify the virus genotype according to the risk of cervical cancer, has acquired European Medical Device Certification (CE-IVD).

'NeoPlex™ HPV29 Detection' kit can identify a total of 29 HPV genotypes that include the high-risk HPV group for cervical cancer development by securing differentiated multi-analysis performance with Genematrix's proprietary C-Tag™ technology.

Since 'NeoPlex™ HPV29 Detection kit' is specifically designed for real-time PCR platforms, which are widely distributed and now becoming more generalized worldwide due to the COVID-19 pandemic, it is now possible to obtain results quickly and easily in the global market.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account